Literature DB >> 26167070

Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Vasiliy Ivanovich Reshetnyak1.   

Abstract

Primary biliary cirrhosis (PBC) is a chronic progressive cholestatic granulomatous, and destructive inflammatory lesion of small intralobular and septal bile ducts, which is likely to be caused by an autoimmune mechanism with a the presence of serum antimitochondrial antibodies and a potential tendency to progress to cirrhosis. Despite the fact that the etiology of this disease has been unknown so far, there has been a considerable body of scientific evidence that can reveal the clinical and laboratory signs of PBC and the individual components of its pathogenesis and elaborate diagnostic criteria for the disease and its symptomatic therapy. Deficiencies in autoimmune tolerance are critical factors for the initiation and perpetuation of the disease. The purpose of this review is to summarize the data available in the literature and the author's findings on clinical and laboratory criteria for the diagnosis of PBC. This review describes the major clinical manifestations of the disease and the mechanisms of its development. It presents the immunological, biochemical, and morphological signs of PBC and their significance for its diagnosis. A great deal of novel scientific evidence for the problem of PBC has been accumulated. However, the inadequate efficiency of therapy for the disease lends impetus to the quest for its etiological factors and to further investigations of its pathogenetic mechanisms and, on this basis, to searches for new methods for its early diagnosis.

Entities:  

Keywords:  Biochemical signs; Clinical criteria; Immunological signs; Laboratory criteria; Morphological signs; Primary biliary cirrhosis

Mesh:

Substances:

Year:  2015        PMID: 26167070      PMCID: PMC4491957          DOI: 10.3748/wjg.v21.i25.7683

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  241 in total

1.  Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis.

Authors:  Hiroto Kita; Shuji Matsumura; Xiao-Song He; Aftab A Ansari; Zhe-Xiong Lian; Judy Van de Water; Ross L Coppel; Marshall M Kaplan; M Eric Gershwin
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice).

Authors:  S SHERLOCK
Journal:  Gastroenterology       Date:  1959-11       Impact factor: 22.682

3.  Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis.

Authors:  Raoul Poupon; Olivier Chazouilleres; Christophe Corpechot; Yves Chrétien
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

4.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Authors:  E J Heathcote
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

5.  Contribution to antimitochondrial antibody production: cleavage of pyruvate dehydrogenase complex-E2 by apoptosis-related proteases.

Authors:  Shuji Matsumura; Judy Van De Water; Hiroto Kita; Ross L Coppel; Takao Tsuji; Kazuhide Yamamoto; Aftab A Ansari; M Eric Gershwin
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

6.  Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids.

Authors:  R J Sokol; M S Straka; R Dahl; M W Devereaux; B Yerushalmi; E Gumpricht; N Elkins; G Everson
Journal:  Pediatr Res       Date:  2001-04       Impact factor: 3.756

Review 7.  Malignancies in primary biliary cirrhosis.

Authors:  Fabio Piscaglia; Elisabetta Sagrini
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-01       Impact factor: 2.566

8.  Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis.

Authors:  Monica Miozzo; Carlo Selmi; Barbara Gentilin; Francesca R Grati; Silvia Sirchia; Sabine Oertelt; Massimo Zuin; M Eric Gershwin; Mauro Podda; Pietro Invernizzi
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

9.  The significance of variations in the distribution of copper in liver disease.

Authors:  S Goldfischer; H Popper; I Sternlieb
Journal:  Am J Pathol       Date:  1980-06       Impact factor: 4.307

10.  Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-/-) mice.

Authors:  Willy Hsu; Weici Zhang; Koichi Tsuneyama; Yuki Moritoki; William M Ridgway; Aftab A Ansari; Ross L Coppel; Zhe-Xiong Lian; Ian Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

View more
  22 in total

1.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

Review 2.  Clinical connection between rheumatoid arthritis and liver damage.

Authors:  Biljana Radovanović-Dinić; Snežana Tešić-Rajković; Valentina Zivkovic; Saša Grgov
Journal:  Rheumatol Int       Date:  2018-04-07       Impact factor: 2.631

3.  The Dynamic Interplay Between Mast Cells, Aging/Cellular Senescence, and Liver Disease.

Authors:  Debjyoti Kundu; Lindsey Kennedy; Vik Meadows; Leonardo Baiocchi; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2020-07-29

Review 4.  Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Lindsey Kennedy; Suthat Liangpunsakul; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2019-04-22       Impact factor: 6.902

Review 5.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945

Review 6.  Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis.

Authors:  Despoina Dimopoulou; Theodoros Dimitroulas; Evangelos Akriviadis; Alexandros Garyfallos
Journal:  Rheumatol Int       Date:  2015-09-28       Impact factor: 2.631

7.  Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis.

Authors:  Saeam Shin; In Ho Moh; Young Sik Woo; Sung Won Jung; Jin Bae Kim; Ji Won Park; Ki Tae Suk; Hyoung Su Kim; Mineui Hong; Sang Hoon Park; Myung Seok Lee
Journal:  World J Gastroenterol       Date:  2017-10-21       Impact factor: 5.742

8.  A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.

Authors:  Marlyn J Mayo; Paul J Pockros; David Jones; Christopher L Bowlus; Cynthia Levy; Imran Patanwala; Bruce Bacon; Velimir Luketic; Raj Vuppalanchi; Sharon Medendorp; Alejandro Dorenbaum; Ciara Kennedy; Patricia Novak; Joan Gu; George Apostol; Gideon M Hirschfield
Journal:  Hepatol Commun       Date:  2019-02-01

Review 9.  Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis.

Authors:  Aleksandar Arsenijevic; C Randall Harrell; Crissy Fellabaum; Vladislav Volarevic
Journal:  Anal Cell Pathol (Amst)       Date:  2017-12-19       Impact factor: 2.916

10.  Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis.

Authors:  Albert Parés; Mitchell Shiffman; Victor Vargas; Pietro Invernizzi; Elizabeth S Malecha; Alexander Liberman; Leigh MacConell; Gideon Hirschfield
Journal:  Liver Int       Date:  2020-03-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.